GE HealthCare Technologies Inc. $GEHC Shares Sold by Douglas Lane & Associates LLC

Key Points

• Douglas Lane & Associates cut its stake in GE HealthCare by 10.6% in Q4, selling 46,707 shares and now holds 393,974 shares worth $32.31 million (about 0.09% of the company).
• Analysts are mixed: the consensus rating is Hold with an average price target of $90.75 (7 Buys, 6 Holds, 1 Sell), while some firms raised targets and Goldman lowered its target to $81.
• GE HealthCare beat Q4 estimates with $1.44 EPS vs $1.40 expected and $5.70B revenue vs $5.60B, set FY2026 guidance of $4.95–5.15 EPS, and announced a $0.035 quarterly dividend (≈0.2% yield).

Douglas Lane & Associates LLC lowered its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 10.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 393,974 shares of the company's stock after selling 46,707 shares during the quarter. Douglas Lane & Associates LLC owned about 0.09% of GE HealthCare Technologies worth $32,314,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Wedge Capital Management L L P NC acquired a new stake in shares of GE HealthCare Technologies in the third quarter valued at about $26,859,000. Temasek Holdings Private Ltd acquired a new stake in shares of GE HealthCare Technologies in the third quarter valued at about $99,922,000. Valicenti Advisory Services Inc. grew its stake in shares of GE HealthCare Technologies by 22.6% in the third quarter. Valicenti Advisory Services Inc. now owns 68,107 shares of the company's stock valued at $5,115,000 after buying an additional 12,550 shares in the last quarter. Locust Wood Capital Advisers LLC grew its stake in GE HealthCare Technologies by 7.1% during the 3rd quarter. Locust Wood Capital Advisers LLC now owns 2,084,337 shares of the company's stock valued at $156,534,000 after purchasing an additional 137,992 shares in the last quarter. Finally, Nan Fung Trinity HK Ltd. acquired a new stake in GE HealthCare Technologies during the 3rd quarter valued at approximately $23,206,000. Institutional investors and hedge funds own 82.06% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Stifel Nicolaus raised their price objective on GE HealthCare Technologies from $95.00 to $98.00 and gave the company a "buy" rating in a research note on Wednesday, February 4th. Morgan Stanley raised their price objective on GE HealthCare Technologies from $80.00 to $85.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 4th. Barclays raised their price objective on GE HealthCare Technologies from $86.00 to $87.00 and gave the company an "equal weight" rating in a research note on Friday, February 6th. Wall Street Zen lowered GE HealthCare Technologies from a "buy" rating to a "hold" rating in a research note on Saturday, March 21st. Finally, The Goldman Sachs Group lowered their price objective on GE HealthCare Technologies from $97.00 to $81.00 and set a "buy" rating for the company in a research note on Thursday. Seven analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $90.75.

GE HealthCare Technologies Price Performance

Shares of GEHC opened at $72.91 on Friday. The firm has a market cap of $33.27 billion, a price-to-earnings ratio of 15.99, a PEG ratio of 1.62 and a beta of 1.17. The stock has a 50 day moving average of $76.25 and a 200-day moving average of $77.91. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 0.91. GE HealthCare Technologies Inc. has a 52 week low of $59.70 and a 52 week high of $89.77.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last issued its earnings results on Wednesday, February 4th. The company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.40 by $0.04. The company had revenue of $5.70 billion during the quarter, compared to analyst estimates of $5.60 billion. GE HealthCare Technologies had a return on equity of 21.35% and a net margin of 10.11%.The business's revenue was up 7.1% on a year-over-year basis. During the same quarter last year, the firm earned $1.45 EPS. GE HealthCare Technologies has set its FY 2026 guidance at 4.950-5.150 EPS. As a group, analysts forecast that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

GE HealthCare Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Friday, April 3rd will be given a $0.035 dividend. The ex-dividend date is Thursday, April 2nd. This represents a $0.14 annualized dividend and a dividend yield of 0.2%. GE HealthCare Technologies's dividend payout ratio (DPR) is presently 3.07%.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies NASDAQ: GEHC is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.

Want to see what other hedge funds are holding GEHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.